


HEALTH SERVICES 2022

BioNexus Gene Lab Corp Rank 21 of 94









HEALTH SERVICES 2022



BioNexus Gene Lab Corp Rank 21 of 94



The relative strengths and weaknesses of BioNexus Gene Lab Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioNexus Gene Lab Corp compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 140% points. The greatest weakness of BioNexus Gene Lab Corp is the variable Cost of Goods and Services Sold, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 123% points above the market average of 92%.

Input Variable	Value in 1000 USD
Assets, Current	7,150
Assets, Non-Current	2,425
Cost of Goods and Services Sold	11,169
Depreciation, Depletion, Amortization	0
General and Administrative Expense	1,204
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	2,329
Long Term Liabilities	66
Operating Costs and Expenses	0
Other Assets	-1,634
Other Compr. Net Income	-234
Other Expenses	291
Other Liabilities	0
Other Net Income	-13
Other Revenues	13,429
Property Plant and Equipment	1,634
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	9,574
Liabilities	2,395
Expenses	12,665
Revenues	13,429
Stockholders Equity	7,180
Net Income	752
Comprehensive Net Income	518
Economic Capital Ratio	214%

